NYSE:TMO 31 July 2025 - 4 December 2025

Thermo Fisher shares traded near $573.57 on December 4, 2025, rebounding sharply from mid-year lows. The company announced a new partnership with GENinCode to distribute a coronary heart disease risk test in the US and EMEA. Institutional ownership stands at about 89%. Market cap is around $218 billion, with a forward P/E of 21–25x.

Thermo Fisher Scientific traded near $590.83 per share late Friday, with a market cap of about $222 billion. Institutional investors, including Global Retirement Partners and Laurel Wealth Advisors, disclosed new or increased stakes. An executive vice president sold $6.43 million in shares. The stock remains near its 52-week high of just over $610.

Thermo Fisher shares closed at $558 on Oct. 21, 2025, up 2.6% after an 11% rally in October. Q3 revenue reached $11.12 billion and adjusted EPS $5.79, both above forecasts. The company completed two major acquisitions and gained FDA clearance for new genomic tests. J.P. Morgan set a $650 price target; analysts remain positive.

Thermo Fisher (TMO) closed at $558.07 on Oct 21, up 2.6% for the day and over 11% in October, rebounding from a 10% year-over-year dip. The company has spent $2 billion on U.S. operations and announced a $4.1 billion deal for Solventum’s filtration business. Q3 results are due Oct 22, with analysts expecting EPS of ~$5.50 and revenue near $10.91 billion. JP Morgan raised its 12-month price target to $650.